samedan logo
 
 
 
spacer
home > ebr > winter 2003 > capturing recombinant proteins
PUBLICATIONS
European Biopharmaceutical Review

Capturing Recombinant Proteins

Recombinant DNA technologies are widely used in the drug discovery process, not only to produce novel, engineered proteins, but also to generate proteins in the quantities required for downstream research. Purifying these proteins remains a bottleneck. This article looks at a novel method to rapidly isolate structurally and functionally intact histidine-tagged recombinant proteins using superparamagnetic beads.

Recombinant DNA (rDNA) technologies are a cornerstone of the biotechnology industry and have revolutionised approaches to the discovery of new medicines. Pioneered by scientists such as Paul Berg, Stanley Cohen and Herbert Boyer in the early 1970s, rDNA methodologies allow scientists to 'cut and paste' DNA to engineer novel proteins, and to transfer DNA from one organism to another. They also provide the means to generate proteins in the quantities required for downstream studies in drug discovery - from target identification, target validation and screening of compound libraries, to ADME-Tox studies.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Beate Rygg Johnsen, Product Manager at Dynal Biotech

Beate Rygg Johnsen is an International Product Manager at Dynal Biotech, Oslo in Norway and is responsible for the company's efforts within the area of proteomics. Beate is driving Dynal Biotech's penetration in drug discovery. She holds a MSc and a Cand Scienct from the University of Oslo, Institute of Biochemistry, and a degree in marketing management from BI, Norwegian School of Management.

spacer
Beate Rygg Johnsen
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Arcis Biotechnology appointments Professor Steve Howell as Non-Executive Chairman

Daresbury, UK, 24 July 2019: Arcis Biotechnology (“Arcis”), the nucleic acid sample preparation solution provider, today announced it has appointed Professor Steve Howell as Non-Executive Chairman of its Board of Directors. Steve takes over the position from Paul Foulger, who was serving as Chairman on an interim basis on behalf of the Board.
More info >>

White Papers

Key to Outsourcing Method Development and Validation A Pragmatic Approach

RSSL

In an industry that is seeing an increasing level of work being outsourced, the Contract Research Organisation (CRO) of choice needs to have proven experience in both the pragmatism and flexibility of the method developer’s mind set and a regulatory background in validation.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement